{
  "metadata": {
    "case_id": 56,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T17:12:03.424324",
    "total_alignments": 3,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/56_NCT03275350.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/56_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.9,
          0.2
        ],
        [
          0.1,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "XR-NTX",
            "type": "ACTIVE_COMPARATOR",
            "description": "Extended-release naltrexone",
            "interventionNames": [
              "Drug: Naltrexone Injectable Suspension"
            ]
          },
          "pred_item": {
            "label": "Extended-release naltrexone (XR-NTX)",
            "type": "EXPERIMENTAL",
            "description": "Participants randomized to receive HIV clinic-based extended-release naltrexone (XR-NTX). This treatment requires complete cessation of opioid use prior to induction.",
            "interventionNames": [
              "Drug: Extended-release naltrexone"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "TAU",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment as usual",
            "interventionNames": [
              "Other: Treatment as usual"
            ]
          },
          "pred_item": {
            "label": "Treatment-as-usual (TAU)",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants randomized to receive treatment-as-usual, consisting of opioid agonist therapy (i.e., buprenorphine, methadone).",
            "interventionNames": [
              "Drug: Treatment-as-usual (Buprenorphine or Methadone)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.98,
          0.15
        ],
        [
          0.2,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Naltrexone Injectable Suspension",
            "description": "Six monthly injections of extended-release naltrexone",
            "armGroupLabels": [
              "XR-NTX"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Extended-release naltrexone",
            "description": "A deep muscle injection of an opioid antagonist that lasts 28 days and eliminates the need for daily dosing. Requires an opioid-free state several days prior to initiation.",
            "armGroupLabels": [
              "Extended-release naltrexone (XR-NTX)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "OTHER",
            "name": "Treatment as usual",
            "description": "Standard treatment for opioid use disorder provided at each HIV clinic",
            "armGroupLabels": [
              "TAU"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Treatment-as-usual (Buprenorphine or Methadone)",
            "description": "Opioid agonist therapy acting as partial (buprenorphine) or full (methadone) agonists at the opioid mu receptor, provided as standard care.",
            "armGroupLabels": [
              "Treatment-as-usual (TAU)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.05
        ],
        [
          0.05
        ],
        [
          0.1
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed",
            "description": "HIV-1 RNA \\<200 copies/ml",
            "timeFrame": "12 weeks and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With HIV Viral Suppression, Complete Case",
            "description": "HIV-1 RNA \\<200 copies/ml",
            "timeFrame": "12 weeks and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": 0,
          "score": 0.1,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With HIV Viral Suppression, Per-protocol",
            "description": "HIV-1 RNA \\<200 copies/ml",
            "timeFrame": "12 weeks and 24 weeks"
          },
          "pred_item": {
            "measure": "Qualitative themes regarding XR-NTX induction experiences and barriers",
            "description": "Themes identified through semi-structured interviews and thematic analysis to assess participant experiences with successful and unsuccessful XR-NTX induction. Key themes included readiness for change, supportive environment, caring interactions, withdrawal anxiety, ambivalence, and medication preferences.",
            "timeFrame": "Interviews conducted between July 2018 and November 2019"
          }
        }
      ]
    }
  ]
}